Akers Biosciences Signs Distribution Agreement for BreathScan OxiChek(TM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Akers Biosciences (AKER) Surges Amid First OxiChek Distribution Agreement
June 27, 2016 9:41 AM EDTAkers Biosciences (NASDAQ: AKER) is surging 45% in early trade after the company announced it signed its first distribution agreement for BreathScan OxiChek" ("OxiChek") with Aero-Med, a division of Cardinal Health, a Fortune 500 health care services organization.
Developed by Akers Bio as part of the Akers Wellness line, OxiChek is the first disposable breath test to rapidly determine levels of oxidative stress in the body by measuring the levels of certain abundant free radicals. Frequent use of OxiChek may help health... More
